--- title: "Aditxt adds $769,230.77 in senior secured convertible notes" url: "https://aibio.space/news/aditxt-adds-769-230-77-senior-secured-convertible-notes/" publisher: "aibio.space (Biotech Investor Relations News)" date: "2026-06-22" section: "Debt Financing" tickers: "OTC:ADTX" source: "https://www.sec.gov/Archives/edgar/data/1726711/000121390026071119/ea0295502-8k_aditxt.htm" summary: "Aditxt sold $769,230.77 of additional senior secured convertible notes for $500,000.00 in cash, and it reported $268,852 of cash at March 31, 2026. The fil" --- By the aibio.space news desk. Sources - [SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1726711/000121390026071119/ea0295502-8k_aditxt.htm) [ADTX](https://aibio.space/companies/aditxt/) 2026-06-22 # Aditxt adds $769,230.77 in senior secured convertible notes Tickers [ADTX](https://aibio.space/companies/aditxt/) Aditxt sold $769,230.77 of additional senior secured convertible notes for $500,000.00 in cash, and it reported $268,852 of cash at March 31, 2026. The filing does not name the investors. ## Key facts - **Company**: Aditxt, Inc. (OTC: ADTX) - **News type**: Debt Financing - **Primary source**: [SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1726711/000121390026071119/ea0295502-8k_aditxt.htm) *Trading screens with price charts. CC0, via rawpixel. The picture shows the field, not the companies named.* ## The amendment and the secured tranche Aditxt, Inc. ([ADTX](https://aibio.space/companies/aditxt/)) entered into Amendment No. 1 to its Note Purchase Agreement on June 22, 2026. The original agreement is dated June 3, 2026, and the company had announced it earlier. The amendment raises the aggregate original principal amount of the newly issued series of senior secured convertible notes to $6,254,355.17. Under the amended agreement, the company and its subsidiary Ignite Proteomics LLC issued an additional $769,230.77 of original principal in notes. The purchase price for those additional notes was $500,000.00, paid by the investors in cash. All of the notes, including the earlier ones, are secured by substantially all of Ignite's assets under a Security and Pledge Agreement with a collateral agent. Aditxt also pledged its equity in Ignite to that collateral agent under a separate Pledge Agreement. The 8-K does not state the interest rate, maturity date or conversion price of the additional notes, and it does not say how the cash will be used. ## Who is named, and who is not The 8-K refers to the buyers only as the investors named in the purchase agreement, and it does not name them. It also does not name the collateral agent. The company states that the notes were sold to accredited investors under Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D, relying partly on the investors' own representations. The filing names no placement agent or advisor. ## Adimune's preclinical programs Aditxt was incorporated in Delaware in 2017 and is headquartered in Mountain View, California. Its main therapeutic work sits in Adimune, Inc., a subsidiary formed in January 2023. Adimune's Apoptotic DNA Immunotherapy platform includes the product candidate ADI-100, which is designed to induce tolerance to glutamic acid decarboxylase, an antigen implicated in type 1 diabetes, psoriasis and some autoimmune diseases of the central nervous system. The company's annual report, filed March 31, 2026, describes ADI-100 as a preclinical product whose first human trial is still pending. It says all preclinical studies have been completed, providing data points that support the drug's potential effectiveness, and that Adimune has engaged a contract research organization for planned trials in psoriasis and type 1 diabetes in Germany. Those claims are the company's own, and the annual report text contains no clinical results. The company is working with the Mayo Clinic on an Investigational New Drug package for the FDA, with a pre-IND meeting expected in the second quarter of 2026. A human trial in Stiff Person Syndrome, a rare disease, is expected to begin in 2026 with 10 to 20 patients, pending approval by an institutional review board and the FDA. The annual report says the trial's primary readouts will be safety and tolerability, along with clinical and immunological signals of tolerance induction. ## Losses, cash and shares Revenue fell to $3,195 in 2025 from $133,985 in 2024. Research and development expense was $3.2 million in 2025, down from $10.9 million in 2024. The net loss widened to $43.1 million from $40.4 million. Cash used in operations rose to $25.7 million from $16.8 million. The company reported $3.2 million in cash and cash equivalents at the end of 2025, according to a quarterly report filed May 20, 2026, and $268,852 at March 31, 2026. Cash at the end of 2024 was $833,031. Against 2025 cash used in operations of $25.7 million, the year-end 2025 balance was small, and the March 2026 balance smaller still. The company had 997,976,543 shares of common stock outstanding on June 22, 2026. The sold notes are convertible, and the filing does not give a conversion price, so the share count that a conversion could add cannot be read from the 8-K. [Report an error](https://aibio.space/reputation/#correction) ## Companies in this story ADTX Aditxt, Inc. OTC ยท United States Open the starter desk ## More in Debt Financing Debt Financing ### [Pelthos amends Horizon venture loan, funds Loans E to H and adds Loans I and J](https://aibio.space/news/pelthos-amends-horizon-venture-loan-funds-loans-e-h-adds-loans/) Oct 30, 2026 Debt Financing ### [Repligen announces $1.0 billion private convertible notes transaction](https://aibio.space/news/repligen-announces-1-0-billion-private-convertible-notes-transaction/) Oct 30, 2026 Debt Financing ### [FOXO to buy Ludwig Enterprises preferred stock with majority voting power](https://aibio.space/news/foxo-buy-ludwig-enterprises-preferred-stock-majority-voting-power/) Oct 29, 2026 --- Source page: https://aibio.space/news/aditxt-adds-769-230-77-senior-secured-convertible-notes/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Aditxt adds $769,230.77 in senior secured convertible notes", 2026-06-22, https://aibio.space/news/aditxt-adds-769-230-77-senior-secured-convertible-notes/